bioage weight loss drug news

A weight loss drug developer's stock soars

BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a weight loss drug.

Yahoo · 1d

A weight loss drug developer's stock soars after a $198 million IPO

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public offering (IPO) price on Thursday.

Seeking Alpha on MSN · 1d

Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO

Weight-loss drug developer BioAge Labs (BIOA) on Wednesday announced the pricing of its upsized initial public offering of 11,000,000 shares of its common stock at a public offering price of $18.00 per share.

BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

FierceBiotech1d

BioAge brings in almost $200M from IPO as obesity biotech joins Nasdaq

BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...

BioAge prices $198M IPO, validating pivot to obesity drug research

The offering, which was upsized twice, will support development of a drug the company believes can boost the effects of ...

devdiscourse1d

Health Highlights: Abortion Pills, Weight-Loss Drugs, and Fluoride Risks

The health news update discusses Washington state's abortion pill stockpile as a safeguard, BioAge's successful IPO, a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results